Dear Editor: An African American man in his 50s presented with a one-year history of a pruritic rash on his anterior shins. His past medical history was significant for a recent diagnosis of diabetes. A physical examination revealed scattered, atrophic, pink/purple papules and plaques with reticular pigment on the bilateral anterior lower legs (Figure 1).
Dear Editor: Tofacitinib is a Janus kinase (JAK) 1/3 inhibitor that has been approved by the United States Food and Drug Administration for the treatment of rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. An increasing number of studies have demonstrated the efficacy of tofacitinib in treatment of alopecia areata (AA).1–6 Treatment duration in these studies
by Andrew J. Krispinsky, MD; Polina V. Rzepka, MD; Farrukh Awan, MD; and Benjamin H. Kaffenberger, MD Drs. Krispinsky, Rzepka, and Kaffenberger are with the Division of Dermatology and Dr. Awan is with the Division of Hematology— all from the Department of Internal Medicine at The Ohio State University Comprehensive Cancer Center in Columbus, Ohio. Funding/disclosures. Dr. Awan
J Clin Aesthet Dermatol. 2019;12(5):11–18 by Nima Milani-Nejad MD, PhD; Catherine Chung, MD; and Jessica Kaffenberger, MD All authors are with the Division of Dermatology in the Department of Internal Medicine at The Ohio State University Wexner Medical Center in Columbus, Ohio. Funding/disclosures. Dr. Kaffenberger is a principal investigator for AbbVie, AnaptysBio, Bristol-Myers, Cara Therapeutics, Celgene, Corrona, Eli
by Viroj Wiwanitkit, MD Professor Wiwanitkit is with Dr. DY Patil University in Pune, India and Joseph Ayobabaalola University in Ikehi-Arakeji, Nigeria. Funding/disclosures. The author has no conflicts of interest relevant to the content of this article. Author response provided by Abrahem Kazemi, MD; Olabola Awosika, MD, MS; and Cheryl Burgess, MD J Clin Aesthet